Literature DB >> 27579316

MicroRNA Expression Signature in Degenerative Aortic Stenosis.

Jing Shi1, Hui Liu1, Hui Wang1, Xiangqing Kong1.   

Abstract

Degenerative aortic stenosis, characterized by narrowing of the exit of the left ventricle of the heart, has become the most common valvular heart disease in the elderly. The aim of this study was to investigate the microRNA (miRNA) signature in degenerative AS. Through microarray analysis, we identified the miRNA expression signature in the tissue samples from healthy individuals (n = 4) and patients with degenerative AS (n = 4). Six miRNAs (hsa-miR-193a-3p, hsa-miR-29b-1-5p, hsa-miR-505-5p, hsa-miR-194-5p, hsa-miR-99b-3p, and hsa-miR-200b-3p) were overexpressed and 14 (hsa-miR-3663-3p, hsa-miR-513a-5p, hsa-miR-146b-5p, hsa-miR-1972, hsa-miR-718, hsa-miR-3138, hsa-miR-21-5p, hsa-miR-630, hsa-miR-575, hsa-miR-301a-3p, hsa-miR-636, hsa-miR-34a-3p, hsa-miR-21-3p, and hsa-miR-516a-5p) were downregulated in aortic tissue from AS patients. GeneSpring 13.1 was used to identify potential human miRNA target genes by comparing a 3-way comparison of predictions from TargetScan, PITA, and microRNAorg databases. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were performed to identify potential pathways and functional annotations associated with AS. Twenty miRNAs were significantly differentially expressed between patients with AS samples and normal controls and identified potential miRNA targets and molecular pathways associated with this morbidity. This study describes the miRNA expression signature in degenerative AS and provides an improved understanding of the molecular pathobiology of this disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27579316      PMCID: PMC4989063          DOI: 10.1155/2016/4682172

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


1. Introduction

Degenerative aortic stenosis (AS), the most common valvular heart disease in the elderly, has become a leading cause for surgical valve replacement in industrialized countries. As a result of rising life expectancy and ageing populations, the global prevalence of AS is increasing and is expected to surpass 10 billion by 2100 [1-3]. Degenerative AS has long been considered a chronic process with gradual deposition of calcium phosphate in the valve occurring with age. However, emerging evidence has indicated that this condition is mediated by the interplay of complex biological processes that include the following: inflammation, cell apoptosis, lipids deposition, renin-angiotensin system activation, remodeling of the extracellular matrix, and bone formation [4-11]. However, the underlying mechanisms that regulate this process remain largely unknown [12, 13]. MicroRNAs (miRNAs) are small, 21–25-nucleotide, endogenous, single-stranded noncoding RNAs that regulate target gene expression by binding messenger RNAs (mRNAs) and inhibiting or reducing translation. A single miRNA can regulate numerous genes, while a single gene can be regulated by multiple miRNAs [14]. miRNAs play a critical role in many physiological processes, and there is a growing body of studies indicating that distinct patterns of altered miRNA expression are associated with specific disease processes [15-19]. In the present study, we explore the miRNA expression signature of degenerative AS to improve our understanding of the molecular alternations in this disease.

2. Methods

2.1. Tissue Samples Collection and RNA Isolation

Written informed consent was obtained from all participants of age and/or via their parents. All procedures in this study were approved by the Ethics Committees of the First Affiliated Hospital of Nanjing Medical University and conformed to the principles outlined in the Declaration of Helsinki. Tissue samples from four healthy controls were obtained from prospective multiorgan donors without cardiovascular pathology in cases in which technical reasons prevented transplantation. Aortic valves from patients with degenerative AS were obtained from four patients who underwent surgical valve replacement. General characteristics of these participants are displayed in Table 1. Gross and histological examination was performed to confirm the presence/absence of AS in each sample. Valve samples were immediately snap-frozen in liquid nitrogen upon collection. Total RNA was extracted using an RNeasy Mini Kit in accordance with the manufacturer's protocol (Qiagen, Hilden, Germany).
Table 1

Characteristics of the participants.

ControlAS p value
Number44ns
Male44ns
Age41.5 ± 10.458.3 ± 4.60.0429
LVEF < 50%00ns
Coronary disease00ns
Diabetes mellitus00ns
Medications00ns

Values are displayed as mean ± standard deviation.

LVEF: left ventricular ejection fraction.

2.2. RNA Labeling and Array Hybridization

miRNA expression was evaluated using Agilent miRNA arrays (V2), which included 723 human and 76 human viral miRNAs from the Sanger database v.10.1 (Agilent Technologies, Foster City, CA). Total RNA was dephosphorylated and ligated with pCp-Cy3 and subsequently hybridized to the arrays. After samples were washed and scanned, using Agilent Scan Control software, the Agilent Feature Extract software v9.5.3 was used to analyze the arrays. Each sample was evaluated in triplicate. miRNA expression data were normalized using a bead-based assay and the locally weighted smooth spline (LOWESS) method. After normalization, all expression values were transformed to a linear scale for statistical analysis.

2.3. Bioinformatic Analysis

GeneSpring 13.1 was used to identify potential human miRNA target genes, which compared TargetScan, PITA, and microRNAorg databases and created a Venn diagram to demonstrate relations among the databases. Gene Ontology (GO) analysis was performed to investigate the biological processes, cellular components, and specific molecular function of differentially expressed coding genes identified. Pathway analysis was used to determine the involvement of coexpressed genes in different biological pathways according to Kyoto Encyclopedia of Genes and Genomes (KEGG).

2.4. Statistical Analysis

Independent Student's t-test was used to determine whether there were any significant differences between the miRNA expression profiles between two groups. p values less than 0.05 (p < 0.05) were considered to be statistically significant. Significant data were further analyzed by cluster analysis, and the expression profiles were visualized with GeneSpring 10.0 (Agilent Technologies).

3. Results

3.1. Unsupervised Hierarchical Cluster Analysis of miRNA Microarray Data

miRNA microarray identified 20 miRNAs with significantly differential expression (>2.0-fold) in AS samples relative to normal controls. Six miRNAs were overexpressed (hsa-miR-193a-3p, hsa-miR-29b-1-5p, hsa-miR-505-5p, hsa-miR-194-5p, hsa-miR-99b-3p, and hsa-miR-200b-3p) and 14 (hsa-miR-3663-3p, hsa-miR-513a-5p, hsa-miR-146b-5p, hsa-miR-1972, hsa-miR-718, hsa-miR-3138, hsa-miR-21-5p, hsa-miR-630, hsa-miR-575, hsa-miR-301a-3p, hsa-miR-636, hsa-miR-34a-3p, hsa-miR-21-3p, and hsa-miR-516a-5p) were downregulated in aortic tissue from AS patients (Table 2). Unsupervised hierarchic clustering was performed based on the 20 differentially expressed miRNAs and displayed as heat map (Figure 1).
Table 2

Six overexpressed and 14 downregulated miRNAs in aortic tissue from AS patients compared to the control group.

Systematic name p valueFC (abs)Regulation
hsa-miR-193a-3p0.0206372.067236Up
hsa-miR-29b-1-5p0.022211.56757Up
hsa-miR-505-5p0.03021113.22606Up
hsa-miR-194-5p0.03680714.95685Up
hsa-miR-99b-3p0.02977215.98001Up
hsa-miR-200b-3p0.02163820.1747Up
hsa-miR-3663-3p0.0429862.063909Down
hsa-miR-513a-5p0.017032.238355Down
hsa-miR-146b-5p0.0400942.244855Down
hsa-miR-19720.0330152.432029Down
hsa-miR-7180.0334612.559791Down
hsa-miR-31380.0026482.69498Down
hsa-miR-21-5p0.0042163.334316Down
hsa-miR-6300.0204923.564175Down
hsa-miR-5750.0299495.137385Down
hsa-miR-301a-3p0.01184920.77046Down
hsa-miR-6360.01017725.1902Down
hsa-miR-34a-3p0.01399325.44595Down
hsa-miR-21-3p0.0230432.11932Down
hsa-miR-516a-5p0.02216941.76603Down
Figure 1

Unsupervised hierarchical clustering identified two distinct groups (control versus AS) based on their miRNA expression profile. Sample names are listed at the top. The names of the significantly (p < 0.05) differentially expressed miRNAs are shown on the right. Twenty miRNAs were expressed differently in target genes analysis.

microRNAorg, TargetScan, and PITA were used to predict the targets of differentially expressed miRNAs in CAVD samples using software GeneSpring 13.1. A Venn diagram was generated to highlight the relations among the 3 databases. There are 1010 overlapping genes identified by all 3 programs, which are most likely to be targets of miRNAs in patients with AS (Figure 2).
Figure 2

The red, green, and blue sets stand for target genes predicted by databases microRNAorg, TargetScan, and PITA, respectively.

3.2. GO and Pathway Analysis

Gene Ontology (http://geneontology.org/) was used to classify the function of up- and downregulated genes from 3 structured networks: biological processes, cellular components, and molecular function. In this study, differentially expressed mRNAs were enriched in numerous biological processes including the following: cell adhesion, homophilic cell adhesion, positive regulation of transcription, negative regulation of JAK-STAT cascade, and positive regulation of G1/S transition of mitotic cell cycle associated with biological processes (Figure 3(a)). Similarly, the following cellular components were affected: nucleus, nucleoplasm, and cytoplasm linked with cellular components (Figure 3(b)), while affected molecular functions include the following: protein binding, zinc ion binding, and transcriptional activator activity involved in molecular functions (Figure 3(c)). Moreover, KEGG pathway analysis identified significantly (p < 0.05) affected pathways including the following: cAMP signaling pathway, vascular smooth muscle contraction, regulation of actin cytoskeleton, neurotrophin signaling pathway, and cGMP-PKG signaling pathway (Figure 4).
Figure 3

GO analysis for differentially expressed mRNAs. (a)–(c) GO analysis according to biological process, cellular component, and molecular function, respectively, ranked by enrichment score (−log10 (p value)).

Figure 4

Pathway analysis based on the KEGG database. Ranked by enrichment score (−log10 (p value)).

4. Discussion

Recent studies have improved our understanding of the mechanisms underlying AS [12, 20]. However, there are not many reports that have investigated the function of miRNAs as they relate to the pathobiology of AS [21-26]. A microRNA expression signature provides a better understanding of the mechanisms of a disease [27]. In the present study, we explored miRNA expression signatures associated with degenerative AS using miRNA microarray analysis. Six overexpressed miRNAs (hsa-miR-193a-3p, hsa-miR-29b-1-5p, hsa-miR-505-5p, hsa-miR-194-5p, hsa-miR-99b-3p, and hsa-miR-200b-3p) and 14 downregulated miRNAs (hsa-miR-3663-3p, hsa-miR-513a-5p, hsa-miR-146b-5p, hsa-miR-1972, hsa-miR-718, hsa-miR-3138, hsa-miR-21-5p, hsa-miR-630, hsa-miR-575, hsa-miR-301a-3p, hsa-miR-636, hsa-miR-34a-3p, hsa-miR-21-3p, and hsa-miR-516a-5p) were identified in patients with AS, relative to normal controls, and their general characteristics and functional annotations were analyzed using bioinformatic tools. There were other miRNA microarrays performed about AS before, and, in these studies, the main cause of AS is calcification of the aortic valves [20, 22]. However, as rheumatic fever remains to be the most important etiological factor in calcific aortic valve disease (CAVD) in China, we do not choose CAVD patients to reduce confounding factors when exploring the mechanisms that underlie degenerative AS. As a limitation of our study, the specific pathways affected by miRNAs and which cause AS remain elusive. Further studies are required to functionally characterize the role of specific candidate miRNAs. In conclusion, the present study improved our understanding of the role of miRNAs in degenerative AS. Our findings provide improved understanding of the molecular alterations in this disease and may provide potential targets for future clinical applications.
  27 in total

Review 1.  Long noncoding RNAs and microRNAs in cardiovascular pathophysiology.

Authors:  Thomas Thum; Gianluigi Condorelli
Journal:  Circ Res       Date:  2015-02-13       Impact factor: 17.367

2.  Circulating MicroRNA-30d Is Associated With Response to Cardiac Resynchronization Therapy in Heart Failure and Regulates Cardiomyocyte Apoptosis: A Translational Pilot Study.

Authors:  Yonathan F Melman; Ravi Shah; Kirsty Danielson; Junjie Xiao; Bridget Simonson; Andreas Barth; Khalid Chakir; Gregory D Lewis; Zachary Lavender; Quynh A Truong; Andre Kleber; Ranendra Das; Anthony Rosenzweig; Yaoyu Wang; David Kass; Jagmeet P Singh; Saumya Das
Journal:  Circulation       Date:  2015-05-20       Impact factor: 29.690

3.  Expression of smooth muscle cell markers and co-activators in calcified aortic valves.

Authors:  Najma Latif; Padmini Sarathchandra; Adrian H Chester; Magdi H Yacoub
Journal:  Eur Heart J       Date:  2014-01-12       Impact factor: 29.983

Review 4.  Calcific aortic valve disease: is it another face of atherosclerosis?

Authors:  I Sathyamurthy; Shaji Alex
Journal:  Indian Heart J       Date:  2015-08-21

Review 5.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease.

Authors:  Katherine E Yutzey; Linda L Demer; Simon C Body; Gordon S Huggins; Dwight A Towler; Cecilia M Giachelli; Marion A Hofmann-Bowman; Douglas P Mortlock; Melissa B Rogers; Mehran M Sadeghi; Elena Aikawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-09-04       Impact factor: 8.311

6.  MicroRNA-125b and chemokine CCL4 expression are associated with calcific aortic valve disease.

Authors:  Pauli Ohukainen; Suvi Syväranta; Juha Näpänkangas; Kristiina Rajamäki; Panu Taskinen; Tuomas Peltonen; Satu Helske-Suihko; Petri T Kovanen; Heikki Ruskoaho; Jaana Rysä
Journal:  Ann Med       Date:  2015-07-30       Impact factor: 4.709

Review 7.  Shear-Sensitive Genes in Aortic Valve Endothelium.

Authors:  Joan Fernández Esmerats; Jack Heath; Hanjoong Jo
Journal:  Antioxid Redox Signal       Date:  2016-01-21       Impact factor: 8.401

8.  miR-21-3p controls sepsis-associated cardiac dysfunction via regulating SORBS2.

Authors:  Hui Wang; Yihua Bei; Shutong Shen; Peipei Huang; Jing Shi; Jialiang Zhang; Qi Sun; Yuanyuan Chen; Yun Yang; Tianzhao Xu; Xiangqing Kong; Junjie Xiao
Journal:  J Mol Cell Cardiol       Date:  2016-03-29       Impact factor: 5.000

9.  Calcific Aortic Valve Disease: Molecular Mechanisms and Therapeutic Approaches.

Authors:  Daniel Alejandro Lerman; Sai Prasad; Nasri Alotti
Journal:  Eur Cardiol       Date:  2015

10.  The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease.

Authors:  Antonella Galeone; Domenico Paparella; Silvia Colucci; Maria Grano; Giacomina Brunetti
Journal:  ScientificWorldJournal       Date:  2013-11-06
View more
  14 in total

Review 1.  Multi-Omics Approaches to Define Calcific Aortic Valve Disease Pathogenesis.

Authors:  Mark C Blaser; Simon Kraler; Thomas F Lüscher; Elena Aikawa
Journal:  Circ Res       Date:  2021-04-29       Impact factor: 17.367

2.  MicroRNA Expression Signature in Human Calcific Aortic Valve Disease.

Authors:  Hui Wang; Jing Shi; Beibei Li; Qiulian Zhou; Xiangqing Kong; Yihua Bei
Journal:  Biomed Res Int       Date:  2017-04-11       Impact factor: 3.411

3.  Specific circulating microRNA signature of bicuspid aortic valve disease.

Authors:  Neus Martínez-Micaelo; Raúl Beltrán-Debón; Isabel Baiges; Marta Faiges; Josep M Alegret
Journal:  J Transl Med       Date:  2017-04-11       Impact factor: 5.531

4.  Analysis of microRNA Expression Profiles Induced by Yiqifumai Injection in Rats with Chronic Heart Failure.

Authors:  Yu Zhao; Yunfei Li; Ling Tong; Xinying Liang; Han Zhang; Lan Li; Guanwei Fan; Yi Wang
Journal:  Front Physiol       Date:  2018-02-06       Impact factor: 4.566

5.  Changes in Whole-Blood microRNA Profiles during the Onset and Treatment Process of Cerebral Infarction: A Human Study.

Authors:  Arata Abe; Mayui Tanaka; Akihito Yasuoka; Yoshikazu Saito; Shinji Okada; Masahiro Mishina; Keiko Abe; Kazumi Kimura; Tomiko Asakura
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

Review 6.  The Genetic Regulation of Aortic Valve Development and Calcific Disease.

Authors:  Vinal Menon; Joy Lincoln
Journal:  Front Cardiovasc Med       Date:  2018-11-06

7.  miR-636: A Newly-Identified Actor for the Regulation of Pulmonary Inflammation in Cystic Fibrosis.

Authors:  Pauline Bardin; Tobias Foussignière; Nathalie Rousselet; Carine Rebeyrol; Joanna C Porter; Harriet Corvol; Olivier Tabary
Journal:  Front Immunol       Date:  2019-11-15       Impact factor: 7.561

8.  MicroRNA-99b-3p promotes angiotensin II-induced cardiac fibrosis in mice by targeting GSK-3β.

Authors:  You-Hui Yu; Yu-Hong Zhang; Yan-Qing Ding; Xue-Ying Bi; Jing Yuan; Hang Zhou; Pan-Xia Wang; Li-Li Zhang; Jian-Tao Ye
Journal:  Acta Pharmacol Sin       Date:  2020-08-19       Impact factor: 6.150

9.  Circulating MicroRNA Profiles Differ between Hyperglycemia and Euglycemia in Coronary Heart Disease Patients.

Authors:  Yunyao Jiang; Nan Liu; Bingjie Xue; Jincai Hou; Chengren Lin; Jianxun Ren; Jianxun Liu
Journal:  Biomed Res Int       Date:  2017-10-30       Impact factor: 3.411

Review 10.  Epigenome alterations in aortic valve stenosis and its related left ventricular hypertrophy.

Authors:  Igor Gošev; Martina Zeljko; Željko Đurić; Ivana Nikolić; Milorad Gošev; Sanja Ivčević; Dino Bešić; Zoran Legčević; Frane Paić
Journal:  Clin Epigenetics       Date:  2017-10-03       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.